Dalma schreef:
[quote=-Anna-]
Ik denk dat het probleem is dat er voorlopig geen heel goed nieuws zal zijn, maar ik kan me vergissen. Als de cijfers komen kan dit aangegrepen worden om de koers weer lager te zetten.
[/quote]
dat er geen goed nieuws te verwachten is binnenkort is natuurlijk onzin:
|||||||||||||||||||||||||||
Sirna Therapeutics Announces Updated Phase I Clinical Trial Data for Sirna-027
Results Presented at the American Academy of Ophthalmology Demonstrate Clinical Benefit of a siRNA Compound in Humans
SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI), a leading RNAi therapeutics company, announced today that one of its clinical investigators, Edward Quinlan, M.D., of the Wilmer Eye Institute at The Johns Hopkins University, presented updated interim data on Sirna's Phase I trial for age-related macular degeneration (AMD). The data continues to demonstrate that Sirna's short interfering RNA (siRNA) molecule, Sirna-027, targeting Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) is safe and well tolerated with 100% of patients showing visual acuity stabilization and 23% of those patients experiencing clinically significant improvement in visual acuity after eight weeks from a single injection. Of equal significance, these latest results showcase the continued demonstration of biological activity in humans of a synthetic siRNA as shown by a relevant decrease in central foveal thickness measured by ocular coherence tomography (OCT).
|||||||||||||||||||||
let ook op de volgende woorden:
|||||||||||||||||||||
During his presentation, Dr. Quinlan concluded that Sirna-027 appears to be safe, well tolerated with no dose limiting toxicities observed. Dr. Quinlan also concluded that all patients in the trial have experienced visual acuity improvement or stabilization at eight weeks from a single dose, while 23% of those patients showed a clinically significant improvement of 3 or more lines on the ETDRS eye chart. He also highlighted that a reduction in central foveal thickness was observed by OCT in the majority of patients.
Sirna-027 clinical investigator, Peter Kaiser, M.D., of the Cole Eye Institute at the Cleveland Clinic, stated, "I have seen with my own patients the clinical results from Sirna-027 and believe that it is a very promising compound that could significantly improve the quality of life for AMD patients. With the trial approaching completion, I am encouraged by these positive results and believe this drug may play an important role in the future treatment of AMD."
|||||||||||||||||||||
bij deze een leuke zin die aanduidt dat er wel degelijk goed nieuws te verwachten is op korte termijn:
|||||||||||||||||||||
"After the completion of the Phase I trial, which is expected by year end 2005, Allergan will assume all developmental responsibilities for Sirna-027 and the two companies anticipate that Sirna-027 will advance to Phase II trials in 2006."
"Sirna Therapeutics is extremely proud of the positive results exhibited by Sirna-027. We believe that future trials will continue to demonstrate Sirna-027's outstanding safety and tolerability profile as well as improved clinical benefit and a more convenient dosing regimen compared to currently marketed or investigational therapies. In addition, we believe that Allergan's expertise in ocular delivery and formulation will enhance the therapeutic benefit of Sirna-027, offering an exciting next generation therapy for patients suffering from AMD."
|||||||||||||||||||||
de kans dat deze resultaten niet op korte termijn bekend worden gemaakt is DUS ZEER KLEIN.
de kans dat deze resultaten niet goed zijn of niet goed ontvangen zullen worden is dus WEDEROM ZEER KLEIN!!